Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression

Abhishek Bhurwal; Hemant Mutneja; Vikas Bansal; Akshay Goel; Shilpa Arora; Bashar Attar; Carlos D. Minacapelli; Gursimran Kochhar; Lea Ann Chen; Steve Brant; Darren Seril

doi:10.1111/apt.16913

Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression

Abhishek Bhurwal, Hemant Mutneja, Vikas Bansal, Akshay Goel, Shilpa Arora, Bashar Attar, Carlos D. Minacapelli, Gursimran Kochhar, Lea Ann Chen, Steve Brant, Darren Seril

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. Methods: Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger’s test. Results: Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates. There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. Conclusion: In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.

Original language	English (US)
Pages (from-to)	1244-1264
Number of pages	21
Journal	Alimentary Pharmacology and Therapeutics
Volume	55
Issue number	10
DOIs	https://doi.org/10.1111/apt.16913
State	Published - May 2022

ASJC Scopus subject areas

Gastroenterology
Pharmacology (medical)
Hepatology

Access to Document

10.1111/apt.16913

Cite this

Bhurwal, A., Mutneja, H., Bansal, V., Goel, A., Arora, S., Attar, B., Minacapelli, C. D., Kochhar, G., Chen, LA., Brant, S., & Seril, D. (2022). Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression. Alimentary Pharmacology and Therapeutics, 55(10), 1244-1264. https://doi.org/10.1111/apt.16913

Bhurwal, A, Mutneja, H, Bansal, V, Goel, A, Arora, S, Attar, B, Minacapelli, CD, Kochhar, G, Chen, LA, Brant, S & Seril, D 2022, 'Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression', Alimentary Pharmacology and Therapeutics, vol. 55, no. 10, pp. 1244-1264. https://doi.org/10.1111/apt.16913

@article{83383183d6eb4fc8bdeb80728634adbf,

title = "Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression",

abstract = "Introduction: There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. Methods: Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger{\textquoteright}s test. Results: Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates. There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. Conclusion: In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.",

author = "Abhishek Bhurwal and Hemant Mutneja and Vikas Bansal and Akshay Goel and Shilpa Arora and Bashar Attar and Minacapelli, {Carlos D.} and Gursimran Kochhar and Lea Ann Chen and Steve Brant and Darren Seril",

note = "Publisher Copyright: {\textcopyright} 2022 John Wiley & Sons Ltd.",

year = "2022",

month = may,

doi = "10.1111/apt.16913",

language = "English (US)",

volume = "55",

pages = "1244--1264",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients

T2 - a systematic review, meta-analysis and meta-regression

AU - Bhurwal, Abhishek

AU - Mutneja, Hemant

AU - Bansal, Vikas

AU - Goel, Akshay

AU - Arora, Shilpa

AU - Attar, Bashar

AU - Minacapelli, Carlos D.

AU - Kochhar, Gursimran

AU - Chen, Lea Ann

AU - Brant, Steve

AU - Seril, Darren

PY - 2022/5

Y1 - 2022/5

N2 - Introduction: There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. Methods: Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger’s test. Results: Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates. There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. Conclusion: In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.

AB - Introduction: There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. Methods: Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger’s test. Results: Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates. There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. Conclusion: In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.

UR - http://www.scopus.com/inward/record.url?scp=85127436154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127436154&partnerID=8YFLogxK

U2 - 10.1111/apt.16913

DO - 10.1111/apt.16913

M3 - Article

C2 - 35355306

AN - SCOPUS:85127436154

SN - 0269-2813

VL - 55

SP - 1244

EP - 1264

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 10

ER -

Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this